These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16278082)

  • 1. Determinants of false positive recall in an Australian mammographic screening program.
    Kavanagh AM; Davidson N; Jolley D; Heuzenroeder L; Chapman A; Evans J; Gertig DM; Amos A
    Breast; 2006 Aug; 15(4):510-8. PubMed ID: 16278082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy, percent mammographic density, and sensitivity of mammography.
    Kavanagh AM; Cawson J; Byrnes GB; Giles GG; Marr G; Tong B; Gertig DM; Hopper JL
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1060-4. PubMed ID: 15894653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy and accuracy of mammographic screening.
    Kavanagh AM; Mitchell H; Giles GG
    Lancet; 2000 Jan; 355(9200):270-4. PubMed ID: 10675074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of digital mammography in a population-based breast cancer screening program: effect of screening round on recall rate and cancer detection.
    Sala M; Comas M; Macià F; Martinez J; Casamitjana M; Castells X
    Radiology; 2009 Jul; 252(1):31-9. PubMed ID: 19420316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy and mammographic screening outcomes in Western Australia.
    Crouchley K; Wylie E; Khong E
    J Med Screen; 2006; 13(2):93-7. PubMed ID: 16792833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Introduction of Digital Mammography in an Organized Screening Program on the Recall and Detection Rate.
    Campari C; Giorgi Rossi P; Mori CA; Ravaioli S; Nitrosi A; Vacondio R; Mancuso P; Cattani A; Pattacini P
    J Digit Imaging; 2016 Apr; 29(2):235-42. PubMed ID: 26537932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hormone replacement therapy use on mammographic screening outcomes.
    Beckmann KR; Farshid G; Roder DM; Hiller JE; Lynch JW
    Cancer Causes Control; 2013 Jul; 24(7):1417-26. PubMed ID: 23649232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of non-attendance for second round mammography in an Australian mammographic screening programme.
    O'Byrne AM; Kavanagh AM; Ugoni A; Diver F
    J Med Screen; 2000; 7(4):190-4. PubMed ID: 11202585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of outcome of mammography in the National Health Service Breast Screening Programme.
    Banks E; Reeves G; Beral V; Bull D; Crossley B; Simmonds M; Hilton E; Bailey S; Barrett N; Briers P; English R; Jackson A; Kutt E; Lavelle J; Rockall L; Wallis MG; Wilson M
    J Med Screen; 2002; 9(2):74-82. PubMed ID: 12133927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.
    Banks E; Reeves G; Beral V; Bull D; Crossley B; Simmonds M; Hilton E; Bailey S; Barrett N; Briers P; English R; Jackson A; Kutt E; Lavelle J; Rockall L; Wallis MG; Wilson M; Patnick J
    Breast Cancer Res; 2006; 8(1):R8. PubMed ID: 16417651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status.
    Kavanagh AM; Giles GG; Mitchell H; Cawson JN
    J Med Screen; 2000; 7(2):105-10. PubMed ID: 11002452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators.
    Otten JD; Karssemeijer N; Hendriks JH; Groenewoud JH; Fracheboud J; Verbeek AL; de Koning HJ; Holland R
    J Natl Cancer Inst; 2005 May; 97(10):748-54. PubMed ID: 15900044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.
    Chiarelli AM; Kirsh VA; Klar NS; Shumak R; Jong R; Fishell E; Yaffe MJ; Boyd NF
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1856-62. PubMed ID: 17035392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme.
    Castells X; Molins E; Macià F
    J Epidemiol Community Health; 2006 Apr; 60(4):316-21. PubMed ID: 16537348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammography Clinical Image Quality and the False Positive Rate in a Canadian Breast Cancer Screening Program.
    Guertin MH; Théberge I; Zomahoun HTV; Dufresne MP; Pelletier É; Brisson J
    Can Assoc Radiol J; 2018 May; 69(2):169-175. PubMed ID: 29706254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiological review of interval cancers in an Australian mammographic screening programme. Radiology Quality Assurance Group of BreastScreen Victoria.
    Amos AF; Kavanagh AM; Cawson J
    J Med Screen; 2000; 7(4):184-9. PubMed ID: 11202584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mammography screening in the county of Copenhagen. Results of the first three screening rounds].
    Tange UB; Hirsch FR; Jensen MB; Olsen AH; Blichert-Toft M; Rank FE; Vejborg IM; Mouridsen H; Lynge E
    Ugeskr Laeger; 2002 Feb; 164(8):1048-52. PubMed ID: 11894707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review.
    Banks E
    J Med Screen; 2001; 8(1):29-34. PubMed ID: 11373847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women.
    May DS; Lee NC; Nadel MR; Henson RM; Miller DS
    AJR Am J Roentgenol; 1998 Jan; 170(1):97-104. PubMed ID: 9423608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial).
    Johns LE; Moss SM;
    Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2758-64. PubMed ID: 20837718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.